Sun Qi of Daotong Capital Confirmed to Attend the 2nd International Summit on Medical Device Innovation

To further analyze the innovation and transformation of China’s medical device industry, gain insights into development trends, and promote the integration of industry and capital, the event is hosted by the People’s Government of Gaochun District, organized by the Gaochun District Science and Technology Bureau and VCBeat, and co-organized by Jiangsu Gaochun High-Tech Industrial Development Zone. “The 2nd International Summit on Medical Device Innovation"will be held onJuly 28, 2020InNanjing · GaochunHosted.

Sun Qi, Founding Managing Partner of DaoTong CapitalConfirming attendance at the 2nd International Summit on Medical Device Innovation.

Sun Qi, Founding Managing Partner of DaoTong Capital

With two decades of experience in the medical device industry, he previously served as Executive President and a key management shareholder of China’s largest medical device import company, held senior executive positions at a main board-listed company, and was a member of the Shanghai Municipal Government’s Expert Group on Economic Operations, the inaugural Committee of Experts for Promoting SME Development in Shanghai, and the Shanghai Youth Federation. He also serves as an off-campus master’s supervisor at the School of Finance, Nankai University. He has received numerous honors, including being named to the “Top 30 Best Early-Stage Investors in China 2018” list by Zero2IPO. Investment portfolio includes Weier’nuo Pediatrics, Deepwise Medical, Shuchuang Surgical Robots, and Heyuan Biology. He holds an EMBA from Cheung Kong Graduate School of Business.

Sun Qi believes that the true competition among medical enterprises lies in the comprehensive and multidisciplinary capabilities of their entire teams. Sun Qi has previously stated that there are “three major hurdles” for AI in healthcare: the first is approval by the China Food and Drug Administration (CFDA), the second is reimbursement, and the third is determining who can move fastest when the path ahead is clear.

At the summit, Mr. Sun Qi will join the morning roundtable discussion as a panelist, alongside Wang Jinhe, Vice President of External Affairs and Market Access at Johnson & Johnson (China); Zhao Xiangwei, Deputy Dean of the School of Biological Science and Medical Engineering at Southeast University; and Yang Song, Chief Healthcare Analyst at Cinda Securities, to discuss medical devices in the post-pandemic era.

In recent years, as a strategic emerging industry strongly supported by the state, China’s medical device sector has enjoyed robust growth momentum, bolstered by a series of policies ranging from deepened review and approval reforms, innovation in high-value consumables, Diagnosis-Related Groups (DRG), Supply, Processing, and Distribution (SPD) models, to medical consortiums, tiered diagnosis and treatment, and the Marketing Authorization Holder (MAH) system for medical devices. Statistics show that the market size of China’s medical device industry reached RMB 628.5 billion in 2019, and is projected to exceed RMB 900 billion by 2022.

The 2nd International Summit on Medical Device Innovationwill be2020 Medical Device Innovation Vitality Listtaking the release as an opportunity to deeply focus onGenetic Testing, In Vitro Diagnosticsand other hot topics, bringing together the most active medical device innovators, listed companies, financial institutions, and healthcare organizations from China and abroad to create a medical device industryOfflineGrand Event.

Future Trends: Four 2020 Medical Device Innovation Vitality Lists Released On-Site

Focusing on Four Hot Tracks in the Medical Device Sector: A Deep Dive into Chemiluminescence, Home Medical Devices, Orthopedic Implants, and Cutting-Edge Tech Products. Who Are the 2020 Most Innovative and Vital Medical Device Companies?At the 2020 Second International Summit on Medical Device Innovation, the 2020 Medical Device Innovation Vitality Rankings will be released. Witness the unveiling of four ranking lists and discover which 40 companies emerge as the most innovative.

Featured Guests: Over 18 Medical Device Industry Leaders to Engage in Dialogue with You

Yuan-Ting Zhang, Academician of the International Academy of Medical and Biological Engineering, and Jie Tian, Director of the Key Laboratory of Molecular Imaging at the Chinese Academy of Sciences, will join forces with executives from the multinational giant Johnson & Johnson, NMPA medical device review experts, founders of high-quality innovative medical device enterprises, forward-looking medical device investors, and senior department directors to discuss the future of medical devices. More guests are being confirmed; stay tuned.

Partially Confirmed Guests:

Zhang Yuanting, Academician of the International Academy of Medical and Biological Engineering, IEEE Fellow, and Fellow of the American Institute for Medical and Biological Engineering

Tian Jie, Director of the Key Laboratory of Molecular Imaging, Chinese Academy of Sciences

Bao Ningzhong, Professor at Nanjing Tech University

Dong Yansheng, NMPA Medical Device Review Expert

Wang Jinhe, Vice President of External Affairs and Market Access, Johnson & Johnson (China)

Sun Qi, Founding Managing Partner of Daotong Capital

Zhao Xiangwei, Deputy Dean of the School of Biological Science and Medical Engineering, Southeast University

Yang Song, Chief Analyst of the Pharmaceutical Industry at Cinda Securities

Wu Hanliang, Director of the Strategy Department, Guotai Junan Securities

Wang Yaqi, Co-founder and Chairman of Raybiotech

Du Zhengping, Co-founder of Aoran Bio    

Zhou Quan, Managing Director at Legend Capital

Qi Hua, Founder of CytoNest Biotech

Guo Yan, Director of the Center for Pathological Diagnosis at Hengdao

Li Gang, Founder of Changjiang Biotech

More speakers to be confirmed...

More guests are being confirmed...

In-Depth Content: Two Roundtables Focus on Industry Trends and the Development Direction of In Vitro Diagnostics

In recent years, domestic medical device innovation has surged. The primary market has seen the emergence of unicorn companies such as United Imaging Healthcare, Venus Medtech, and MicroPort CardioFlow. In the secondary market, Mindray Medical’s market capitalization has exceeded RMB 300 billion, while Chunli Medical’s stock price has increased more than tenfold over two years. By segment, China’s in vitro diagnostics (IVD) market reached RMB 60.4 billion in 2018, representing an 18.4% year-on-year growth. It is projected to maintain an annual growth rate of approximately 18%, making China one of the fastest-growing IVD markets globally.

All these signs seem to indicate that the golden age of domestically produced medical devices has arrived. What trends will shape the future development of China’s medical device industry? Which sub-sectors within the domestic medical device market hold greater promise for growth? At this summit, the morning roundtable discussion will focus onPost-Pandemic Medical DevicesDevelopment Opportunities: The afternoon roundtable session will delve into specialized subfields,andSenior Investors in the In Vitro Diagnostics Industry: Precision Dialogue with High-Quality Innovative Enterprises。